Biogen and Eisai Report Data from Long-Term Extension Phase 1b Study of Investigational Alzheimer’s Disease Treatment Aducanumab

World News: . []

CAMBRIDGE Mass Aug 28 2018 GLOBE NEWSWIRE -- LINK  BIIB and Eisai Co Ltd Headquarters Tokyo CEO Haruo Naito Eisai announced results from a LINK  analysis of the ongoing LINK  extension LTE Phase 1b study of aducan umab, a...

More news and information about Biogen Inc.

Published By:

Globe Newswire: 12:30 GMT Tuesday 28th August 2018

Published: .

Search for other references to "biogen" on SPi News


Previous StoryNext Story

SPi News is published by Sector Publishing Intelligence Ltd.
© Sector Publishing Intelligence Ltd 2019. [Admin Only]
Sector Publishing Intelligence Ltd.
Agriculture House, Acland Road, DORCHESTER, Dorset DT1 1EF United Kingdom
Registered in England and Wales number 07519380.
Privacy Policy | Terms and Conditions | Contact Us